



CIC participates in Congenica's Series B extension

£23.3 million raised in Series B

Proceeds will be used to accelerate international expansion and development of next generation Sapiencia™ platform

30 April 2019

Cambridge Innovation Capital plc (CIC), the venture capital investor focused on technology and life science businesses in the Cambridge ecosystem, has participated in a £13.3 million extension to Congenica's Series B funding, thus increasing the total amount raised in the company's Series B round to £23.3 million. Digital China Health Technologies Corporation Limited (DCHealth) joins as a new strategic investor, building on an existing strategic partnership with Congenica, investing alongside follow-on funding from existing investors.

Congenica was recently awarded a multi-year contract to be the exclusive provider of Diagnostic Decision Support Services for the world leading NHS Genomic Medicine Service, allowing clinicians to use its Sapiencia™ platform and expert support services to interrogate the human genome to identify disease-causing variants. The company is now looking to accelerate growth, with commercial scale-up to support further penetration into international markets and expand on the company's initial focus on the US and China.

In addition, the new capital will drive the development of an enhanced product platform that harnesses the power of statistics and machine learning technology to augment the ability of users to make diagnostic decisions. In parallel, new versions of the company's Sapiencia™ platform will incorporate extensive automation and broaden the clinical and commercial focus to support cancer treatment decisions, pharmacogenomics and health management.

Dr David Atkins, CEO of Congenica, said, "With the formalisation of our partnership with the NHS, we are now focused on accelerating the introduction of important new features to our platform. These funds will allow us to automate Sapiencia™, to support wider usage and reduce costs to healthcare providers, helping more clinicians provide accurate, rapid and cost-effective diagnoses to patients and their families.

"In addition, we can now begin to penetrate international markets. The deepening of our relationship with DCHealth gives us greater insight into the needs of the China market, with the recent development of an on-premise version of our platform the most notable example."

Dr Michael Anstey, Investment Director at CIC, added, "Congenica was one of the first companies in which CIC invested. Over the last four years, the company has successfully established Sapiencia™ as a globally leading platform to provide high quality variant interpretation of genome sequences. It is very exciting to see the company successfully achieving its ambition to improve lives by enabling the delivery of genomic medicine and we are delighted to continue to support Congenica as it seeks to scale internationally."

Dr Andy Richards, Chairman of Congenica, said, "Congenica is at the exciting scale-up stage of its commercial development, at the forefront of the fast-moving genomics market. Its recent successes demonstrate that, with the right investment and leadership, world-leading technology



companies can be built from UK science. With this additional investment, Congenica is poised to become the leading clinical genomics service provider and will benefit patients globally.”

- ENDS -

About Cambridge Innovation Capital plc

Cambridge Innovation Capital (CIC) is a venture capital investor focused on intellectual property rich technology and life science businesses in the Cambridge ecosystem. CIC is committed to building leading businesses from brilliant technologies. It combines a unique relationship with the University of Cambridge with deep financial and industry links to support these businesses as they seek to fulfil their potential to change the world of tomorrow.

For more information please visit www.cicplc.co.uk or follow us on Twitter at @CambsInnovation

About Congenica

Congenica is the provider of the diagnostic decision support platform, Sapiaientia™, and associated clinical services, which enable clinicians to interrogate the human genome to identify disease-causing variants.

80% of rare diseases are thought to have a genetic component, and patients wait an average of 4.7 years, and typically see 7.4 different clinical specialists, before getting a diagnosis. Sapiaientia™ enables clinicians to progress through workflows more quickly, optimizing throughput of patients, number of patients diagnosed and reducing costs.

Headquartered in Cambridge, UK, and with a footprint in the US and China, Congenica is born out of pioneering research from the Wellcome Trust Sanger Institute and the NHS. Congenica was a partner for the pivotal Genomics England 100,000 Genomes Project and is now the exclusive provider of Diagnostic Decision Support Services for the NHS Genomic Medicine Service.

About Sapiaientia™

Sapiaientia™ combines heritage from the Wellcome Trust Sanger Institute with real-world commercial and clinical experience through work with Genomics England's 100K Genomes Project, NHS Genomic Medicine Centres and NHS Trusts across the UK. Sapiaientia™ helps clinicians quickly identify the genetic variants that cause disease to support clinical decision-making. It has also played a role in a number of other significant national-scale genomics projects including China's 100K Wellness Project.



For more information please contact:

Cambridge Innovation Capital

+44 (0)1223 764875

Michael Anstey, Investment Director

Louise Rich, Head of Investor Relations and Communications

Consilium Strategic Communications (City, financial PR)

+44 (0)20 3709 5700

Mary-Jane Elliott

CIC@consilium-comms.com

Sukaina Virji

www.consilium-comms.com

Lindsey Neville

Holdsworth Associates (local and trade PR)

+44 (0)1954 202789

Rachel Holdsworth

Rachel@holdsworth-associates.co.uk